LT97200A - N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimas - Google Patents

N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimas

Info

Publication number
LT97200A
LT97200A LT97-200A LT97200A LT97200A LT 97200 A LT97200 A LT 97200A LT 97200 A LT97200 A LT 97200A LT 97200 A LT97200 A LT 97200A
Authority
LT
Lithuania
Prior art keywords
aminoindan
propargyl
enantiomer
salts
compositions
Prior art date
Application number
LT97-200A
Other languages
English (en)
Other versions
LT4455B (lt
Inventor
Moussa B. Youdim
John P. M. Finberg
Ruth Levy
Jeffrey Sterling
David Lerner
Haim Yellin
Alex Veinberg
Original Assignee
Teva Pharmaceutical Industries, Ltd.
Technion Research And Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23772591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT97200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries, Ltd., Technion Research And Development Foundation Ltd. filed Critical Teva Pharmaceutical Industries, Ltd.
Publication of LT97200A publication Critical patent/LT97200A/lt
Publication of LT4455B publication Critical patent/LT4455B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
LT97-200A 1995-05-22 1997-12-22 N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimas LT4455B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/446,439 US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

Publications (2)

Publication Number Publication Date
LT97200A true LT97200A (lt) 1998-09-25
LT4455B LT4455B (lt) 1999-01-25

Family

ID=23772591

Family Applications (1)

Application Number Title Priority Date Filing Date
LT97-200A LT4455B (lt) 1995-05-22 1997-12-22 N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimas

Country Status (21)

Country Link
US (6) US5744500A (lt)
EP (1) EP0828485A4 (lt)
JP (1) JP3341898B2 (lt)
KR (1) KR100412154B1 (lt)
CN (1) CN1096853C (lt)
AU (1) AU699090B2 (lt)
BR (1) BR9608733A (lt)
CA (1) CA2221458A1 (lt)
CZ (1) CZ288724B6 (lt)
EE (1) EE03741B1 (lt)
HU (1) HUP9901629A3 (lt)
IL (1) IL118247A (lt)
LT (1) LT4455B (lt)
LV (1) LV12083B (lt)
MX (1) MX9708977A (lt)
NO (1) NO975331L (lt)
NZ (1) NZ308866A (lt)
PL (1) PL184124B1 (lt)
RU (1) RU2203653C2 (lt)
SK (1) SK283675B6 (lt)
WO (1) WO1996037199A1 (lt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
WO2001030339A1 (en) 1999-10-27 2001-05-03 Teva Pharmaceutical Industries, Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
EP1441708B1 (en) 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
DK1567152T3 (da) 2002-11-15 2013-10-07 Teva Pharma Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
CN1605336A (zh) 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
EP1686973A4 (en) 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
WO2006014968A2 (en) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
JP5738509B2 (ja) * 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
US8022104B2 (en) * 2005-02-24 2011-09-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulations of ladostigil tartrate
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP1888056A4 (en) * 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
FR2886549B1 (fr) * 2005-06-06 2007-09-07 Biocodex Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1956904B1 (en) * 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Low-dose ladostigil for the treatment of mild cognitive impairment
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
US20110047685A1 (en) * 2006-02-16 2011-03-03 Ferrara Vincent R Impact energy management method and system
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
WO2007117431A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
CN101062897B (zh) * 2006-04-25 2011-11-23 重庆医药工业研究院有限责任公司 一种制备2，3-二氢-1h-茚-1-胺及其衍生物的改进方法
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
NZ577623A (en) * 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
EP2276722A2 (en) * 2008-03-28 2011-01-26 Medichem, S.A. Polymorphic form of an aminoindan mesylate derivative
CN102123980B (zh) 2008-06-02 2014-05-07 基因里克斯(英国)有限公司 用于制备对映异构纯胺的方法
EP2280929B1 (en) * 2008-06-02 2018-01-31 Generics [UK] Limited An improved process for the preparation of rasagiline
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
EA201170018A1 (ru) * 2008-06-13 2011-08-30 Тева Фармасьютикал Индастриз, Лтд. Разагилин для изменения течения болезни паркинсона
CN102065853A (zh) * 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
EP2328861A2 (en) 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
CA2731164A1 (en) * 2008-07-30 2010-02-04 Generics (Uk) Limited Polymorphic form of rasagiline mesylate
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2417101B1 (en) * 2009-04-09 2013-10-23 Merck Sharp & Dohme B.V. Indane derivatives
CA2767592A1 (en) 2009-07-09 2011-01-13 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
US8741962B2 (en) * 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
EP2939669A1 (en) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
EP2531181B1 (en) 2010-02-03 2019-04-10 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
CN108186611A (zh) 2010-04-30 2018-06-22 帝国制药美国公司 丙炔基氨基茚满透皮组合物
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
WO2012050594A1 (en) 2010-09-01 2012-04-19 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
MX2013004598A (es) 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
EP2827848B1 (en) 2012-03-21 2016-04-27 Synthon BV Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
US9205061B2 (en) 2012-11-02 2015-12-08 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
ES2502140T1 (es) * 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
US20160022572A1 (en) * 2013-03-13 2016-01-28 N To B Ltd. Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
CN103804200B (zh) * 2014-02-21 2015-04-29 常州市第四制药厂有限公司 雷沙吉兰及其类似物的制备方法
WO2020214886A1 (en) * 2019-04-17 2020-10-22 Vici Health Sciences LLC Liquid pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513244A (en) * 1894-01-23 Island
US3201470A (en) * 1965-08-17 Chsx c cech
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB1037014A (en) 1963-08-02 1966-07-20 Aspro Nicholas Ltd Derivatives of 1-aminoindane
US3513249A (en) * 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
EP0258096B1 (fr) 1986-08-21 1992-09-09 Roussel-Uclaf Dérivés de l'indane, leur procédé de préparation, leur application à titre de médicaments, les compositions pharmaceutiques les renfermant et les intermédiaires obtenus
HU197510B (en) 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
FR2626877B1 (fr) 1988-02-05 1991-04-05 Delalande Sa Ethers alkyliques ou benzyliques du phenol, leurs procedes de preparation et leur application en therapeutique
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
JPH04504760A (ja) 1989-09-25 1992-08-20 アメリカ合衆国 炎症性反応の検出およびストレスに対する応答の予測をするための評価方法
ES2097155T3 (es) 1989-10-02 1997-04-01 Cima Labs Inc Forma de dosificacion efervescente y metodo de administracion.
FR2655044B1 (fr) 1989-11-24 1995-03-03 Delalande Sa Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique.
JPH03176457A (ja) 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CA2039742A1 (en) 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
DE69227467T2 (de) 1991-12-24 1999-04-22 Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo Intrabukkal desintegrierende zubereitung und ihre herstellung
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
SE501848C2 (sv) 1992-11-18 1995-06-06 Kvaerner Pulping Tech Metod att koka massa kontinuerligt vid konstant temperatur
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
PT814789E (pt) 1995-03-02 2003-09-30 Scherer Technologies Inc R P Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2319318A1 (en) * 1998-01-27 1999-07-29 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
FI104042B1 (fi) * 1998-09-29 1999-11-15 Aaro Kiuru Menetelmä keuhkojen perfuusion mittaamiseksi
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060009483A1 (en) * 2002-05-31 2006-01-12 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
US20040115254A1 (en) * 2002-09-06 2004-06-17 Genteric, Inc. Microcapsules and methods of use
DK1567152T3 (da) * 2002-11-15 2013-10-07 Teva Pharma Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
JP5738509B2 (ja) * 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤

Also Published As

Publication number Publication date
LV12083A (lv) 1998-07-20
WO1996037199A8 (en) 1999-08-12
JP2000508292A (ja) 2000-07-04
CN1191481A (zh) 1998-08-26
PL323470A1 (en) 1998-03-30
US5744500A (en) 1998-04-28
NO975331D0 (no) 1997-11-20
US6630514B2 (en) 2003-10-07
EE03741B1 (et) 2002-06-17
AU5872396A (en) 1996-12-11
CN1096853C (zh) 2002-12-25
EP0828485A4 (en) 1998-12-02
SK157497A3 (en) 1998-05-06
PL184124B1 (pl) 2002-09-30
US20030065038A1 (en) 2003-04-03
HK1015269A1 (en) 1999-10-15
US20060094783A1 (en) 2006-05-04
HUP9901629A3 (en) 2000-03-28
HUP9901629A2 (hu) 2000-02-28
US20030212145A1 (en) 2003-11-13
US6316504B1 (en) 2001-11-13
CZ369997A3 (cs) 1999-06-16
LV12083B (en) 1998-09-20
CZ288724B6 (cs) 2001-08-15
IL118247A0 (en) 1996-09-12
IL118247A (en) 2002-07-25
WO1996037199A1 (en) 1996-11-28
US6956060B2 (en) 2005-10-18
CA2221458A1 (en) 1996-11-28
SK283675B6 (sk) 2003-11-04
EE9700310A (et) 1998-06-15
RU2203653C2 (ru) 2003-05-10
NZ308866A (en) 1999-09-29
NO975331L (no) 1998-01-20
AU699090B2 (en) 1998-11-19
LT4455B (lt) 1999-01-25
BR9608733A (pt) 1999-12-07
KR19990021896A (ko) 1999-03-25
KR100412154B1 (ko) 2004-07-05
MX9708977A (es) 1998-03-31
JP3341898B2 (ja) 2002-11-05
US20070100001A1 (en) 2007-05-03
EP0828485A1 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
EP0828485A4 (en) USE OF THE R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDANE, ITS SALTS AND COMPOSITIONS
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
MX192025B (en) Cosmetic composition, preparation and application of same
IL116851A0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
NL300295I2 (nl) 3,3-diarylpropylaminen, de toepassing en bereidinghiervan
HUP0900587A3 (en) Stable salts of 3,3-diphenylpropylamines and preparation thereof
HUP9801817A3 (en) Dolastatin derivatives, their preparation and use
ZA971964B (en) Azolobenzazepine derivatives and compositions and method of use thereof.
GB9525812D0 (en) Composition and use
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
HUP9901685A3 (en) Colchicine derivatives, the use thereof and formulations containing them
IL117981A0 (en) Compositions containing 2-oxetanones their preparation and use
HUP0105075A3 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives, their use and pharmaceutical compositions containing them
HUP9801880A3 (en) Novel cryptophycins, their use and pharmaceutical compositions containing them
ZA966063B (en) Synergistic herbicidal composition and method of use thereof.
HUP0102025A3 (en) Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
IL118443A0 (en) Cycloalkane-benzylidene derivatives their preparation and use
EP0852503A4 (en) AGENTS FOR THE TREATMENT OF DIARRHÖ, THEIR USE AND PRODUCTION
HUP9802590A3 (en) Indan-, benzothiophene-, benzofuran- and indolesulfonamide derivatives, their use and pharmaceutical compositions containing them
IL123092A0 (en) Pyrazol-4-ylbenzoyl derivatives their preparation and use
NZ323282A (en) N,n'-bridged bisindolylmaleimides and their use to prepare n,n'-bridged bisindolylmaleimides
HRP960400B1 (en) New carbonic acid derivatives, their preparation and their use
GB2324090B (en) 5,6-O-alkylidene glucono-1(4)-lactones and derivatives thereof,their preparation and use
IL118547A0 (en) Aqueous film-formimg compositions and their use
AU4605399A (en) Novel 3,4-diaminophenol derivatives and their use

Legal Events

Date Code Title Description
ND9D Filing a supplementary protection certificate

Free format text: PRODUCT NAME: RASAGILINUM (N-PROPARGIL-1-(R)-AMINOINDANO MEZILATAS); REGISTRY NO: EU//1/04/304/001-007; REGISTRY DATE: 20050221

Spc suppl protection certif: PA2005007

Filing date: 20050819

SPCF Filing an spc

Free format text: PRODUCT NAME: RASAGILINUM (N-PROPARGIL-1-(R)-AMINOINDANO MEZILATAS); REGISTRATION NO/DATE: EU/1/04/304/001, EU/1/04/304/002, EU/1/04/304/003, EU/1/04/304/004, EU/1/04/304/005, EU/1/04/304/006, EU/1/04/304/007 20050221

Spc suppl protection certif: PA2005007

Filing date: 20050819

Expiry date: 20160522

SPCG Grant of an spc

Free format text: PRODUCT NAME: RASAGILINUM (N-PROPARGIL-1-(R)-AMINOINDANO MEZILATAS); REGISTRATION NO/DATE: EU/1/04/304/001, EU/1/04/304/002, EU/1/04/304/003, EU/1/04/304/004, EU/1/04/304/005, EU/1/04/304/006, EU/1/04/304/007 20050221

Spc suppl protection certif: PA2005007,C4455

Filing date: 20050819

Expiry date: 20160522

Extension date: 20200222

MK9A Expiry of a patent

Effective date: 20160522